Lopinavir/ritonavir monotherapy as second-line antiretroviral treatment in resource-limited settings: Week 104 analysis of AIDS clinical trials group (ACTG) A5230

• Main Authors: Kumarasamy N., Aga E., Ribaudo H., Wallis C., Katzenstein D., Stevens W., Norton M., Klingman K., Hosseinipour M., Crump J., Supparatpinyo K., Badal-Faesen S., Bartlett J.
• 格式: Article
• 出版: Oxford University Press 2015
• 主題: Medicine (all); Infectious Diseases; Microbiology (medical)
• 在線閱讀: http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84929223931&origin=inward; http://cmuir.cmu.ac.th/handle/6653943832/38485

© 2015 The Author. Background. The AIDS Clinical Trials Group (ACTG) A5230 study evaluated lopinavir/ritonavir (LPV/r) monotherapy following virologic failure (VF) on first-line human immunodeficiency virus (HIV) regimens in Africa and Asia. Methods. Eligible subjects had received first-line regimen...